Boyar Asset Management Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,157 shares of the company’s stock after purchasing an additional 414 shares during the quarter. Johnson & Johnson accounts for approximately 2.8% of Boyar Asset Management Inc.’s holdings, making the stock its 13th biggest position. Boyar Asset Management Inc.’s holdings in Johnson & Johnson were worth $3,299,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in JNJ. BlackRock Inc. raised its stake in shares of Johnson & Johnson by 0.6% in the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock valued at $27,242,005,000 after buying an additional 1,168,129 shares in the last quarter. Morgan Stanley grew its holdings in shares of Johnson & Johnson by 0.3% in the 1st quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after purchasing an additional 54,563 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Johnson & Johnson by 88.0% in the 2nd quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after purchasing an additional 8,062,204 shares during the last quarter. Swiss National Bank grew its holdings in shares of Johnson & Johnson by 1.4% in the 2nd quarter. Swiss National Bank now owns 11,304,866 shares of the company’s stock worth $1,589,803,000 after purchasing an additional 157,100 shares during the last quarter. Finally, California Public Employees Retirement System grew its holdings in shares of Johnson & Johnson by 8.9% in the 3rd quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock worth $1,580,626,000 after purchasing an additional 864,547 shares during the last quarter. Hedge funds and other institutional investors own 67.44% of the company’s stock.
Shares of JNJ stock opened at $146.36 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The company has a market capitalization of $385.30 billion, a P/E ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. The company’s 50 day moving average price is $145.51 and its two-hundred day moving average price is $146.57. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping the consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period last year, the company posted $2.12 EPS. Analysts forecast that Johnson & Johnson will post 7.99 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.01 dividend. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.76%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is owned by company insiders.
A number of equities research analysts have commented on JNJ shares. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a report on Friday. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Cantor Fitzgerald increased their price objective on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Credit Suisse Group raised their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Finally, Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus target price of $164.93.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: What are popular green investing opportunities?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.